MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Abierto

SectorSanidad

15.64 2.42

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

14.62

Máximo

15.69

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	5.766 63.808
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+30.21% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.6B
Apertura anterior	13.22
Cierre anterior	15.64

Noticias sobre sentimiento de mercado

By Acuity

50%

162 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 abr 2026, 23:26 UTC

Acciones populares

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 abr 2026, 20:41 UTC

Principales Movimientos del Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 abr 2026, 23:49 UTC

Charlas de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 abr 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 abr 2026, 22:51 UTC

Charlas de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 abr 2026, 22:08 UTC

Ganancias

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 abr 2026, 22:06 UTC

Ganancias

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

16 abr 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Health Care Roundup: Market Talk

16 abr 2026, 20:49 UTC

Ganancias

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 abr 2026, 20:43 UTC

Ganancias

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

16 abr 2026, 20:40 UTC

Charlas de Mercado

Ganancias

Netflix Says Engagement Quality Hits New High -- Market Talk

16 abr 2026, 20:30 UTC

Acciones populares

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 abr 2026, 20:25 UTC

Ganancias

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 abr 2026, 20:23 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 abr 2026, 20:19 UTC

Ganancias

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 abr 2026, 20:17 UTC

Ganancias

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 abr 2026, 20:16 UTC

Ganancias

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

30.21% repunte

Estimación a 12 Meses

Media 20 USD 30.21%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

162 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.